Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: A cost-effectiveness analysis

American Journal of Transplantation

Volumn 14, Issue 3, 2014, Pages 629-634

  Wright, A J ^a   Fishman, J A ^a   Chung, R T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cost effectiveness; health economics; hepatitis B virus; liver transplantation; prophylaxis

Indexed keywords

EMTRICITABINE; ENTECAVIR; HEPATITIS B CORE ANTIBODY; LAMIVUDINE; TENOFOVIR;

ADD ON THERAPY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; GRAFT RECIPIENT; HEALTH CARE; HEPATITIS B; HUMAN; LIVER GRAFT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

COST-EFFECTIVENESS; HEALTH ECONOMICS; HEPATITIS B VIRUS; LIVER TRANSPLANTATION; PROPHYLAXIS;

ADENINE; ANTIVIRAL AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION TREES; FOLLOW-UP STUDIES; GRAFT SURVIVAL; GUANINE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; MARKOV CHAINS; ORGANOPHOSPHONATES; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL RATE;

EID: 84896695729     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12598     Document Type: Article

References (30)

1. Kim WR, Stock PG, Smith JM, et al. OPTN/SRTR 2011 annual data report: Liver. Am J Transplant 2013; 13: S73-S102.
2. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP., Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-1742.
3. Bohorquez HE, Cohen AJ, Girgrah N, et al. Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: A 13-year experience. Liver Transpl 2013; 19: 611-618.
4. Nery JR, Nery-Avila C, Reddy KR, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 75: 1179-1186.
5. Levitsky J, Doucette K, AST Infectious Diseases Community of Practice. Viral hepatitis in solid organ transplantation. Am J Transplant 2013; 13: S147-S168.
6. Cholongitas E, Papatheodoridis GV, Burroughs AK., Liver grafts from anti-hepatitis B core positive donors: A systematic review. J Hepatol 2010; 52: 272-279.
7. Chang MS, Olsen SK, Pichardo EM, et al. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: A 12-year experience. Transplantation 2013; 95: 960-965.
8. Jain A, Orloff M, Abt P, et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 2005; 37: 3187-3189.
9. Lok AS, McMahon BJ., Chronic hepatitis B: Update 2009. Hepatology 2009; 50: 661-662.
10. Thomson Corporation. Red book: Pharmacy's fundamental reference. Montvale, NJ: Thomson PDR, 2013.
11. Schoening WN, Buescher N, Rademacher S, et al. Twenty-year longitudinal follow-up after orthotopic liver transplantation: A single-center experience of 313 consecutive cases. Am J Transplant 2013; 13: 2384-2394.
12. United States Life Tables, 1999-2009. Available at: http://www.cdc.gov/ nchs/nvss/mortality/lewk3.htm. Accessed September 15, 2013.
13. Yaprak O, Dayangac M, Balci D, Demirbas T, Yuzer Y, Tokat Y., Use of livers from hepatitis B core antibody positive donors in living donor liver transplantation. Hepatogastroenterology 2010; 57: 1268-1271.
14. Chotiyaputta W, Pelletier SJ, Fontana RJ, Lok AS., Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int 2010; 4: 707-715.
15. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
16. Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2013; doi: 10.1002/hep.26686 [Epub ahead of print].
17. Thomson Healthcare. Micromedex® healthcare series [Internet database]. 2013. Available at: http://www.micromedexsolutions.com. Accessed August 1, 2013.
18. Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 2011; 55: 1235-1240.
19. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S., Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10: 941-946, quiz e68.
20. Angelico M, Nardi A, Marianelli T, et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study. J Hepatol 2013; 58: 715-723.
21. Woo G, Tomlinson G, Yim C, et al. Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol 2012; 26: 445-451.
22. Hoerger TJ, Schillie S, Wittenborn JS, et al. Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes. Diabetes Care 2013; 36: 63-69.
23. Centers for Medicare & Medicaid Services. 2013. Available at: http://www.cms.gov/. Accessed August 1, 2013.
24. Arteaga-Rodriguez A, Carrasco-Garrido P, Andres de Lopez A, Santos J, Gil de Miguel A, Jiménez-García R., Trends of acute hepatitis B hospitalizations, comorbidities, fatality rate, and costs associated with the hospitalization in Spain (2001-2006). Eur J Gastroenterol Hepatol 2010; 22: 961-966.
25. Dasta JF, McLaughlin TP, Mody SH, Piech CT., Daily cost of an intensive care unit day: The contribution of mechanical ventilation. Crit Care Med 2005; 33: 1266-1271.
26. Strasfeld L, Chou S., Antiviral drug resistance: Mechanisms and clinical implications. Infect Dis Clin North Am 2010; 24: 413-437.
27. Fabrega E, Garcia-Suarez C, Guerra A, et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: A new approach. Liver Transpl 2003; 9: 916-920.
28. Roque-Afonso AM, Feray C, Samuel D, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002; 50: 95-99.
29. Ganem D, Prince AM., Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
30. Seem DL, Lee I, Umscheid CA, Kuehnert MJ, United States Public Health Service. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep 2013; 128: 247-343.